Dr. Patel is an expert in the treatment of myeloproliferative neoplasms, myelodysplastic syndromes, and leukemia. He is an active researcher whose work is focused on the development of clinical trials to investigate novel therapies that may improve the standard of care for patients with myeloid cancers and leukemia. Dr. Patel has published his research in several well-respected peer-reviewed journals including Blood, Blood Advances, the British Journal of Haematology, Cancer, JCI Insight, and Bone Marrow Transplantation.
University of Chicago
Chicago, IL
Fellowship - Hematology-Oncology
2021
McGaw Medical Center of Northwestern University
Chicago, IL
Chief Residency - Internal Medicine
2018
McGaw Medical Center of Northwestern University
Chicago, IL
Residency - Internal Medicine
2017
University of Missouri School of Medicine
Columbia, MO
MD - Medicine
2014
Northwestern University
Evanston, IL
BA - Economics
2010
Echocardiographic high-output heart failure is associated with worse survival among patients with myelofibrosis.
Echocardiographic high-output heart failure is associated with worse survival among patients with myelofibrosis. Cardiooncology. 2026 Mar 11.
PMID: 41814386
Impact of statin use on cardiovascular and hematologic outcomes among patients with myeloproliferative neoplasms.
Impact of statin use on cardiovascular and hematologic outcomes among patients with myeloproliferative neoplasms. Blood Adv. 2026 Mar 10; 10(5):1603-1613.
PMID: 41499780
Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopenias.
Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopenias. Blood Adv. 2026 Mar 10; 10(5):1746-1755.
PMID: 41499760
Ruxolitinib and heart failure outcomes among patients with myelofibrosis.
Ruxolitinib and heart failure outcomes among patients with myelofibrosis. Leuk Lymphoma. 2026 Mar 05; 1-8.
PMID: 41784313
Targeting menin in T-lineage acute lymphoblastic leukemia.
Targeting menin in T-lineage acute lymphoblastic leukemia. Mol Cancer Ther. 2026 Mar 04.
PMID: 41778833
Low Serum Cholesterol Is a Biomarker of Advanced Disease and Poor Outcomes in Myeloproliferative Neoplasms.
Low Serum Cholesterol Is a Biomarker of Advanced Disease and Poor Outcomes in Myeloproliferative Neoplasms. Blood Adv. 2026 Mar 04.
PMID: 41779966
Impact of modernizing eligibility criteria on enrollment and representation in acute myeloid leukemia clinical trials.
Impact of modernizing eligibility criteria on enrollment and representation in acute myeloid leukemia clinical trials. Blood. 2026 Feb 05; 147(6):639-649.
PMID: 41100728
Hematologic complications in patients exposed to poly-ADP ribose polymerase inhibitors.
Hematologic complications in patients exposed to poly-ADP ribose polymerase inhibitors. Haematologica. 2026 Jan 29.
PMID: 41609051
Clinical and sociodemographic predictors of intensive care unit admission following chemotherapy in acute myeloid leukemia.
Clinical and sociodemographic predictors of intensive care unit admission following chemotherapy in acute myeloid leukemia. Haematologica. 2026 Jan 15.
PMID: 41537345
Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with =5% blasts: An International TP53 Investigators Network (iTiN) study.
Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with =5% blasts: An International TP53 Investigators Network (iTiN) study. Cancer. 2026 Jan 01; 132(1):e70210.
PMID: 41417597